ロード中...
An emerging treatment option for glaucoma: Rho kinase inhibitors
Rho kinase (ROCK) inhibitors are a novel potential class of glaucoma therapeutics with multiple compounds currently in Phase II and III US Food and Drug Administration trials in the United States. These selective agents work by relaxing the trabecular meshwork through inhibition of the actin cytoske...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4025933/ https://ncbi.nlm.nih.gov/pubmed/24872673 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OPTH.S41000 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|